Regulus Therapeutics
RGLS
#7307
Rank
A$0.83 B
Marketcap
A$12.11
Share price
0.00%
Change (1 day)
420.50%
Change (1 year)

Regulus Therapeutics (RGLS) - Cash on Hand

Cash on Hand as of March 2025 : A$97.01 Million

According to Regulus Therapeutics's latest financial reports the company has A$97.01 Million in cash and cash equivalents.
A companyโ€™s cash on hand also refered as cash/cash equivalents (CCE) and Short-term investments, is the amount of accessible money a business has.

Regulus Therapeutics - Cash on Hand chart (from 2011 to 2025)

Cash on Hand by year

Year Cash on Hand Change
2024-12-31A$0.12 B249.23%
2023-12-31A$34.88 M-39.38%
2022-12-31A$57.54 M-30.91%
2021-12-31A$83.28 M106.01%
2020-12-31A$40.42 M-17.04%
2019-12-31A$48.73 M146.37%
2018-12-31A$19.78 M-74.29%
2017-12-31A$76.94 M-27.12%
2016-12-31A$0.10 B-32.56%
2015-12-31A$0.15 B-19.78%
2014-12-31A$0.19 B52.72%
2013-12-31A$0.12 B35.39%
2012-12-31A$94.39 M153.76%
2011-12-31A$37.2 M

Cash on Hand for similar companies or competitors

Company Cash on Hand differencediff. Country
Sanofi
SNY
A$10.75 B 10,987.15%๐Ÿ‡ซ๐Ÿ‡ท France
Biogen
BIIB
A$1.90 B 1,865.79%๐Ÿ‡บ๐Ÿ‡ธ USA
Bristol-Myers Squibb
BMY
A$18.67 B 19,146.42%๐Ÿ‡บ๐Ÿ‡ธ USA
AstraZeneca
AZN
A$7.37 B 7,500.05%๐Ÿ‡ฌ๐Ÿ‡ง UK
GSK plc
GSK
A$5.83 B 5,910.43%๐Ÿ‡ฌ๐Ÿ‡ง UK
Sangamo Therapeutics
SGMO
A$40.94 M-57.80%๐Ÿ‡บ๐Ÿ‡ธ USA
Dicerna Pharmaceuticals
DRNA
N/AN/A๐Ÿ‡บ๐Ÿ‡ธ USA
Alnylam Pharmaceuticals
ALNY
A$5.32 B 5,387.79%๐Ÿ‡บ๐Ÿ‡ธ USA